TNDM vs. INSP, NARI, IRTC, PRCT, NVST, SLNO, TMDX, LIVN, ENOV, and NVCR
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), LivaNova (LIVN), Enovis (ENOV), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.
Tandem Diabetes Care vs.
Tandem Diabetes Care (NASDAQ:TNDM) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.
Inspire Medical Systems has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.
Tandem Diabetes Care presently has a consensus target price of $45.38, suggesting a potential upside of 124.41%. Inspire Medical Systems has a consensus target price of $228.82, suggesting a potential upside of 38.36%. Given Tandem Diabetes Care's higher probable upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than Inspire Medical Systems.
94.9% of Inspire Medical Systems shares are held by institutional investors. 2.2% of Tandem Diabetes Care shares are held by insiders. Comparatively, 4.1% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Tandem Diabetes Care received 394 more outperform votes than Inspire Medical Systems when rated by MarketBeat users. However, 61.66% of users gave Inspire Medical Systems an outperform vote while only 61.02% of users gave Tandem Diabetes Care an outperform vote.
Inspire Medical Systems has a net margin of 6.67% compared to Tandem Diabetes Care's net margin of -14.84%. Inspire Medical Systems' return on equity of 8.19% beat Tandem Diabetes Care's return on equity.
In the previous week, Tandem Diabetes Care had 8 more articles in the media than Inspire Medical Systems. MarketBeat recorded 9 mentions for Tandem Diabetes Care and 1 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 1.51 beat Tandem Diabetes Care's score of 1.36 indicating that Inspire Medical Systems is being referred to more favorably in the news media.
Tandem Diabetes Care has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
Summary
Inspire Medical Systems beats Tandem Diabetes Care on 13 of the 18 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
This page (NASDAQ:TNDM) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy TNDM Stock Free TNDM Stock Alerts